HeartBeam, Inc. announced it has received a notice of allowance from The United States Patent and Trademark Office for a key patent relating to the initial AI capability in the form of an expert system for its HeartBeam AIMIGoTM System. The patent is entitled, “Hand Held Device for Automatic Cardiac Risk and Diagnostic Assessment.” HeartBeam has developed the HeartBeam AIMIGo System, a personal, portable and easy-to-use VECG solution to assist patients and their clinicians in assessing cardiac symptoms. HeartBeam's breakthrough solution employs a reusable, credit card-sized, VECG recording device and cloud-based software to deliver critical data to clinicians in real-time outside of a medical setting. More than 127 million people in the US have cardiovascular disease, including more than 20 million with coronary artery disease.

The newly allowed patent describes a system that combines the recorded cardiac signals from the HeartBeam AIMIGo VECG device with the patient's symptoms and cardiac risk factors to calculate a cardiac risk score, providing simplified diagnostic information and actionable instructions to the patient. It aims to replicate the decision-making process a physician uses when assessing a patient with cardiac symptoms but performed remotely in an automated manner.